| Dr Andrew Phillips, DO | |
|
901 N Porter Ave Ofc, Norman, OK 73071-6404 | |
| (405) 307-5340 | |
| Not Available |
| Full Name | Dr Andrew Phillips |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 901 N Porter Ave Ofc, Norman, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295256162 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0219R (Oklahoma) | Primary |
| Entity Name | Norman Regional Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912563727 PECOS PAC ID: 2769395185 Enrollment ID: O20031111000299 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Farmers Union Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184639122 PECOS PAC ID: 7517949415 Enrollment ID: O20040603001383 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20050207000313 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Mercy Hospital Logan County, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306126818 PECOS PAC ID: 4587836200 Enrollment ID: O20121004000289 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Oklahoma Emergency Physician Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891039764 PECOS PAC ID: 0345493649 Enrollment ID: O20130118000115 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Mercy Hospital Kingfisher, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1285064618 PECOS PAC ID: 5395970180 Enrollment ID: O20140416000368 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Emergency Physicians Of Mid-america Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063825297 PECOS PAC ID: 2062638661 Enrollment ID: O20140716001692 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Entity Name | Premier Physician Staffing 2 Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326509407 PECOS PAC ID: 3375886476 Enrollment ID: O20190513000686 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Phillips, DO 901 N Porter Ave Ofc, Norman, OK 73071-6404 Ph: () - | Dr Andrew Phillips, DO 901 N Porter Ave Ofc, Norman, OK 73071-6404 Ph: (405) 307-5340 |
News Archive
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers - a significant step toward developing new drugs that might target these cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever.
Mice lose their fear of territorial rivals when a tiny piece of their brain is neutralized, a new study reports.
› Verified 2 days ago
Jonathan Wright I, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Attention Physician Residency, Norman, OK 73071 Phone: 405-307-5340 | |
Dr. Olivia Danielle Reed, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Dr. Spencer Robert Baird, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 706-296-1258 | |
Dr. Dylan Rommel, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1000 | |
Arthur Maduabia, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-5340 | |
Crystal Helena Goree, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 | |
Robert Francisco Sanchez, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 901 N Porter Ave, Norman, OK 73071 Phone: 405-307-1392 |